18F]FB-IL2 PET combined with multi-parametric MRI to analyze treatment-induced changes in tumor microenvironment in advanced cervical cancer

18F]FB-IL2 PET combined with multi-parametric MRI to analyze treatment-induced changes in tumor microenvironment in advanced cervical cancer - IL2 PET imaging and MRI in T cell respons

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45627

Enrollment

Registered

2017-08-25

Start date

2018-02-07

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

18F]FB-IL2 PET imaging

Multi-parametric MRI

T cell respons

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: has signed informed consent histologically confirmed advanced cervical cancer and eligible for chemoradiotherapy

Exclusion criteria

Exclusion criteria: Pre-existing auto-immune disease The use of corticosteroids (at the start of treatment). Contraindication for MRI (e.g. metallic foreign body, heart pacemaker, severe claustrophobia ) eGFR

Design outcomes

Primary

Measure	Time frame
The [18F]FB-IL2 uptake in tumor lesions and its relationship with the number of CD25+ T lymphocytes in biopsy specimens.	—

Secondary

Measure	Time frame
To assess changes in perfusion, diffusion restriction on MRI in response to chemoradiotherapy To correlate the findings between [18F]FB-IL2 PET and pathology with possible changes in perfusion and diffusion, as observed by multi-parameter MRI.	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)